 The stock price of Alnylam Pharmaceuticals, a pharmaceutical company focused on RNA interference therapeutics for genetically defined diseases, plunged over 15 in yesterdays trading session, following its Q3 results, which were much lower than the Wall Street estimates. The company reported. 